

May 2, 2017
Announcement 1365

Drug Use Review (DUR) Board Approves Changes to MSM Chapter 1200

The Nevada Medicaid Drug Use Review (DUR) Board met on July 28, 2016, and October 27, 2016, and voted to adopt the following changes effective April 27, 2017:

Drug Class	Changes
Monoclonal Antibody Agents	Added criteria to include Nucala® and Cinqair®
Duloxetine	Removed clinical prior authorization requirements
Hepatitis C Direct-acting antivirals	Updated to include current treatment guidelines and added criteria for Zepatier®
Irritable-Bowel Syndrome Agents	Added criteria for linaclotide, lubiprostone, alosetron, eluxadoline and rifaximin
GnRH Analogs	Criteria added for use in children under age 18 years old

The following change will be effective May 15, 2017. See [Web Announcement 1334](#).

Drug Class	Changes
Opioids	Added quantity limits for daily max and initial fill days supply limitation